Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 13, 2009

View Archived Issues

Boehringer Ingelheim divulges new B-Raf kinase inhibitors for cancer

Array BioPharma and Genentech jointly develop new Akt protein kinase inhibitors for cancer

Novel gamma-secretase inhibitors developed at Schering-Plough

Gilead scientists describe new TLR7 agonists in recent patent

Recent AstraZeneca patent imparts new bacterial DNA gyrase inhibitors

Novel progesterone receptor ligands in development at Bayer Schering Pharma

New deuterium-enriched ezetimibe analogues disclosed by Protia researchers

Novel angiotensin AT2 receptor antagonists disclosed by Servier

Astellas patent covers EP4 receptor antagonists and their use in treating chronic renal failure

Gilead divulges new HIV reverse transcriptase inhibitors

Celsion commences pivotal phase I/II ThermoDox study in breast cancer

FDA issues complete response letter for Risperdal Consta

Genaera presents preliminary phase Ib trodusquemine results

Raltegravir efficacy sustained through 96 weeks, cancer incidence low in HIV studies

C-peptide reduces lung inflammation in hemorrhagic shock model

Breast cancer risk declines following discontinuation of estrogen plus progestin therapy

Interim efficacy analysis for Riquent trial indicates continuation is futile

RAP-041 displays antiangiogenic and antitumor activity

Phase I clinical evaluation of new recombinant factor IX product begins

Osiris reports positive data on stem cell treatment for acute myocardial infarction

DOR BioPharma signs partnering agreement with Sigma-Tau for orBec

Indian DCGI grants market authorization to Emergent's BioThrax anthrax vaccine

National Cancer Institute accepts PharmaGap's PhG-alpha-1 for testing

License agreement signed for elinogrel

Novelos signs agreement for NOV-002 with Mundipharma, closes private placement with Purdue Pharma

Merck & Co. acquires Insmed's follow-on biologics platform

Palatin receives payments from AstraZeneca related to melanocortin receptor collaboration

Adding methotrexate, methylprednisolone to IFN-beta1a not beneficial in relapsing-remitting MS

Ono Pharmaceutical updates recent progress

Gel formulation of UC-781 found suitable for rectal use in humans

Hydroxyfasudil enhances learning and memory in aged rats

Savient updates pegloticase BLA

Cubist starts first-in-human trial for Clostridium difficile infections

Genentech commences pivotal phase II GDC-0449 trial in basal cell carcinoma

Novartis to develop ASA-404 in breast cancer

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...